Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Traunmüller, F.
Right arrow Articles by Thalhammer, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Traunmüller, F.
Right arrow Articles by Thalhammer, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 47, 229-231
© 2001 The British Society for Antimicrobial Chemotherapy

Brief report

Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients

Friederike Traunmüllera, Renate Thalhammer-Scherrerb, Gottfried J. Lockerc, Heidrun Losertc, Rainer Schmidb, Thomas Staudingerc and Florian Thalhammera,d,*

a Division of Infectious Diseases, b Department of Laboratory Medicine, c Intensive Care Unit, Department of Internal Medicine I and d Institute of Virology, University of Vienna, Austria

The present study was performed to analyse the pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration (CVVH) with a high-flux polyamide membrane. Twelve patients received 500 mg levofloxacin intravenously. The mean levofloxacin concentration peak was 1.9 ± 1.0 mg/L. The elimination half-life, haemofiltration clearance and total removal were 8.3 ± 2.6 h, 27.6 ± 8.4 mL/min and 56 ± 19%, respectively. Further multiple-dose studies are required to enable dosage recommendations to be made for patients receiving renal replacement therapy with CVVH.

* Correspondence address. Department of Internal Medicine I, Division of Infectious Diseases, University of Vienna, Waehringer Guertel 18–20, A-1090 Vienna, Austria. Tel: +43-1-40-400-4440; Fax: +49-89-2443-18-696; E-mail: florian.thalhammer{at}akh-wien.ac.at


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
A. M. M. Y. Li, C. D. Gomersall, G. Choi, Q. Tian, G. M. Joynt, and J. Lipman
A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data?
J. Antimicrob. Chemother., November 1, 2009; 64(5): 929 - 937.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
D. Czock, C. Husig-Linde, A. Langhoff, T. Schopke, C. Hafer, K. de Groot, S. Swoboda, E. Kuse, H. Haller, D. Fliser, et al.
Pharmacokinetics of Moxifloxacin and Levofloxacin in Intensive Care Unit Patients Who Have Acute Renal Failure and Undergo Extended Daily Dialysis
Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1263 - 1268.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
V. Fuhrmann, P. Schenk, W. Jaeger, S. Ahmed, and F. Thalhammer
Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration
J. Antimicrob. Chemother., October 1, 2004; 54(4): 780 - 784.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
F. Traunmuller, P. Schenk, C. Mittermeyer, R. Thalhammer-Scherrer, K. Ratheiser, and F. Thalhammer
Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients
J. Antimicrob. Chemother., January 1, 2002; 49(1): 129 - 134.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.